Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Obesity Management and Cardiovascular Disease
Author(s): Miao Gao , Tanjot Singh , Ramzi Ajjan Added: 4 days ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Targeting Obesity for Heart Failure
Author(s): Emily Morris , Oliver J Rider Added: 3 months ago

Cardiovascular Renal Metabolic

Heart Failure
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 5 months ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF
Author(s): Barry Borlaug Added: 6 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT… View more

Cardiovascular Renal Metabolic

Heart Failure
ERA 25: Treating Obesity in 2025 and Beyond
Author(s): Ruben Nogueiras Added: 10 months ago
ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease… View more

Cardiovascular Renal Metabolic
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology
Author(s): Chim C Lang , Bianca Rocca , Samira Bell Added: 6 months ago
In this short discussion, join Prof Chim Lang (University of Dundee, Dundee, UK), Guest Editor of the upcoming Special Focus on Obesity in Focus, Prof Bianca Rocca (LUM University, Casamassima, IT) and Dr Samira Bell (University of Dundee, Dundee, UK) to discover the implications of obesity on heart failure, kidney disease, and pharmacology.This conversation sets the stage for the upcoming… View more

Cardiovascular Renal Metabolic

Heart Failure
Managing Obesity in HF: 2025 ACC Scientific Statement
Author(s): Michelle Kittleson Added: 8 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific… View more

Cardiovascular Renal Metabolic

Heart Failure
Advancements in Obesity Management (AOM)
Author(s): Harold Bays , Naveed Sattar , Lydia Alexander , et al Added: 1 year ago
The on-demand version of Advancements in Obesity Management (AOM) 2024 explores the intricate links between obesity and cardiovascular disease, providing key insights in evolving diagnostic and treatment strategies.This event, led by Course DirectorsDr Harold Bays (Louisville Metabolic and Atherosclerosis Research Centre, US) and Prof Naveed Sattar (University of Glasgow, UK) brings together a… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Glucagon-Containing Dual and Triple Agonists For Obesity and MASH
Author(s): Scott Harris Added: 1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D
Author(s): Harold Bays Added: 9 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once… View more

Cardiovascular Renal Metabolic